Chemomab Therapeutics (NASDAQ:CMMB) Stock Price Up 1.3% – Time to Buy?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) shares rose 1.3% during trading on Friday . The company traded as high as $1.58 and last traded at $1.55. Approximately 29,971 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 235,683 shares. The stock had previously closed at $1.53.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $25.00.

Chemomab Therapeutics Trading Up 1.3%

The company has a 50 day moving average price of $1.72 and a 200 day moving average price of $1.69. The company has a market capitalization of $11.16 million, a P/E ratio of -0.70 and a beta of 0.64.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its earnings results on Thursday, May 14th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.18). As a group, sell-side analysts forecast that Chemomab Therapeutics Ltd. Sponsored ADR will post -0.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Chemomab Therapeutics

Several large investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC acquired a new stake in shares of Chemomab Therapeutics during the 4th quarter worth about $132,000. Kestra Private Wealth Services LLC grew its stake in Chemomab Therapeutics by 19.3% in the 1st quarter. Kestra Private Wealth Services LLC now owns 61,710 shares of the company’s stock valued at $97,000 after buying an additional 10,000 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Chemomab Therapeutics in the 4th quarter valued at about $31,000. 46.05% of the stock is owned by institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.